@OpenAI: To go deeper on our new Life Sciences model series, research lead @joyjiao12 and product lead Yunyun Wang joined @Andre…
Summary
OpenAI announced a new Life Sciences model series designed for biology, drug discovery, and translational medicine, with research and product leads discussing the development approach on the OpenAI Podcast.
View Cached Full Text
Cached at: 04/20/26, 09:39 AM
To go deeper on our new Life Sciences model series, research lead @joyjiao12 and product lead Yunyun Wang joined @AndrewMayne on the OpenAI Podcast to discuss how we’re building models for biology, drug discovery, and translational medicine. They cover both the opportunity and
Similar Articles
@OpenAI: GPT-Rosalind, our Life Sciences model series, is optimized for scientific workflows, with stronger performance in prote…
OpenAI releases GPT-Rosalind, a specialized life sciences model optimized for protein reasoning, chemical analysis, genomics, and scientific workflows.
AI models need more data about biology, and OpenAI is paying to create it
OpenAI Foundation funds initiatives to create high-quality datasets for AI in biology and medicine, aiming to overcome data limitations that hinder medical breakthroughs.
@ajaymisraaa: Launching o11 for Life Sciences. For the past few months, we have been working with some of the largest pharmaceutical …
o11, an AI agent for enterprise apps, launches specifically for the life sciences sector, targeting pharmaceutical and life science companies. The product is backed by prominent investors including Y Combinator, Accel, and OpenAI.
Introducing new capabilities to GPT-Rosalind
OpenAI introduces an updated GPT-Rosalind model purpose-built for life sciences research, with improved performance in medicinal chemistry, genomics, and drug-discovery workflows, and new benchmarks like LifeSciBench and MedChemBench.
@itsolelehmann: if you've been paying attention, you know there's been a serious vibe shift in AI this month 3 major AI labs (anthropic…
Three major AI labs — Anthropic, OpenAI, and Amazon — have made significant moves into biology this month, signaling a major industry shift toward AI-driven life sciences as the next frontier of value creation.